metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Investigación en enfermedades infecciosas
Journal Information
Vol. 26. Issue S15.
La especialidad de enfermedades infecciosas en España: una asignatura pendiente
Pages 40-50 (December 2008)
Share
Share
Download PDF
More article options
Vol. 26. Issue S15.
La especialidad de enfermedades infecciosas en España: una asignatura pendiente
Pages 40-50 (December 2008)
Full text access
Investigación en enfermedades infecciosas
Infectious Diseases Research
Visits
5336
Jordi Carratalàa,
Corresponding author
jcarratala@ub.edu

Correspondencia: Servicio de Enfermedades Infecciosas. Hospital Universitari de Bellvitge. Feixa Llarga, s/n. 08907 L’Hospitalet de Llobregat. Barcelona. España.
, José Alcamíb, Elisa Corderoc, José M. Miród, José Manuel Ramose
a Servicio de Enfermedades Infecciosas. Hospital Universitari de Bellvitge-IDIBELL. Universitat de Barcelona. L’Hospitalet de Llobregat. Barcelona. España
b Unidad de Inmunopatología del Sida. Instituto de Salud Carlos III. Madrid. España
c Servicio de Enfermedades Infecciosas. Hospital Virgen del Rocío. Sevilla. España
d Servicio de Enfermedades Infecciosas. Hospital Clínic-IDIBAPS. Universitat de Barcelona. Barcelona. España
e Unidad de Enfermedades Infecciosas. Hospital General Universitario de Elche. Alicante. España
This item has received
Article information

En los últimos años, la actividad investigadora en enfermedades infecciosas en España ha experimentado un impulso importante. La Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) acoge actualmente en su seno a 10 grupos de estudio en los que cooperan infectólogos y microbiólogos de distintos centros y que mantienen una actividad investigadora significativa. El programa de Redes Temáticas de Investigación Cooperativa en Salud ha constituido un marco apropiado para la coordinación estratégica de grupos de investigadores de distintas comunidades autónomas. La Red Española para la Investigación en Patología Infecciosa (REIPI) y la Red de Investigación en Sida (RIS) se han consolidado como plataformas que integran investigadores en enfermedades infecciosas de distintos grupos y que llevan a cabo regularmente proyectos de investigación de notable envergadura. La existencia en nuestro país de diversos modelos experimentales en patología infecciosa en instituciones de distintas comunidades autónomas supone un activo importante. Un análisis de la producción científica reciente en enfermedades infecciosas muestra que España ocupa un buen lugar en el contexto de la Unión Europea. La actividad investigadora en enfermedades infecciosas realizada en nuestro país representa una magnífica oportunidad para la formación de especialistas en esta área de conocimiento.

Palabras clave:
Enfermedades infecciosas
Investigación
Redes de Investigación
Sida
Modelos experimentales
Producción científica

There has been a significant increase in research activity into infectious diseases in Spain in the last few years. The Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) currently has ten study groups, with the cooperation of infectious diseases specialists and microbiologists from different centres, with significant research activity. The program of Redes Temáticas de Investigación Cooperativa en Salud (Special Topics Cooperative Health Research Networks) is an appropriate framework for the strategic coordination of research groups from the Spanish autonomous communities. The Spanish Network for Research in Infectious Diseases (REIPI) and the Network for Research in AIDS (RIS) integrate investigators in Infectious Diseases from multiple groups, which continuously perform important research projects. Research using different experimental models in infectious diseases, in numerous institutions, is an important activity in our country. The analysis of the recent scientific production in Infectious Diseases shows that Spain has a good position in the context of the European Union. The research activity in Infectious Diseases carried out in our country is a great opportunity for the training of specialists in this area of knowledge.

Key words:
Infectious Diseases
Investigation
Research Networks
AIDS
Experimental models
Scientific production
Full text is only aviable in PDF
Bibliografía
[1.]
H. Varmus.
Retroviruses.
Science, 240 (1998), pp. 1427-1435
[2.]
R.C. Gallo.
History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2.
Oncogene, 24 (2005), pp. 5926-5930
[3.]
Centers for Disease Control and Prevention.
Pneumocystis pneumoniae-Los Angeles.
Morbid Mortal Wkly Rep, 30 (1981), pp. 250-252
[4.]
F. Barré-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, et al.
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
Science, 220 (1983), pp. 868-871
[5.]
J. Silberner.
AIDS blood screen approved.
Sci News, 127 (1985), pp. 48
[6.]
S. Wain-Hobson, P. Sonigo, O. Danos, S. Cole, M. Alizon.
Nucleotide sequence of the AIDS virus, LAV.
Cell, 40 (1985), pp. 9-17
[7.]
R. Pomerantz, D. Horn.
Twenty years of therapy for HIV-1 infection.
Nat Med, 9 (2003), pp. 867-873
[8.]
E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, M.J. O'Sullivan, et al.
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
N Engl J Med, 331 (1994), pp. 1173-1180
[9.]
J.W. Mellors, A. Muñoz, J.V. Giorgi, J.B. Margolick, C.J. Tassoni, P. Gupta, et al.
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
Ann Intern Med, 126 (1997), pp. 946-954
[10.]
X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, et al.
Viral dynamics in human immunodeficiency virus type 1 infection.
Nature, 373 (1995), pp. 117-122
[11.]
Y. Feng, C.C. Broder, P.E. Kennedy, E.A. Berger.
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science, 272 (1996), pp. 872-877
[12.]
T. Dragic, V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, K.A. Nagashima, et al.
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CCCKR-5.
Nature, 381 (1996), pp. 667-673
[13.]
A.M. Caro-Murillo, J. Castilla, S. Pérez-Hoyos, J.M. Miró, D. Podzamczer, R. Rubio, et al.
Spanish cohort of naïve HIV-infected patients (CoRIS): rationale, organization and initial results.
Enferm Infecc Microbiol Clin, 25 (2007), pp. 23-31
[14.]
Handbook of animal models of infection,
[15.]
García de la María., F. Marco, J.M. Miro, The Hospital Clinic Experimental Endocarditis Study Group.
Modelling systems in bacterial disease: What do they tell us?.
Eur Infect Dis, 2 (2008), pp. 2-5
[16.]
J.L. Mainardi, L. Gutmann, J. Acar, F. Goldstein.
Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis.
Antimicrob Agent Chemother, 39 (1995), pp. 1984-1987
[17.]
J. Gavaldà, C. Torres, C. Tenorio, P. López, M. Zaragoza, J.A. Capdevila, et al.
Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.
Antimicrob Agents Chemother, 43 (1999), pp. 639-646
[18.]
J. Gavaldá, O. Len, J.M. Miró, P. Muñoz, M. Montejo, A. Alarcón, et al.
Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.
Ann Intern Med, 146 (2007), pp. 574-579
[19.]
J. Gavaldá, P.L. Onrubia, M.T. Gómez, X. Gomis, J.L. Ramírez, O. Len, et al.
Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.
J Antimicrob Chemother, 52 (2003), pp. 514-517
[20.]
L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr, A.F. Bolger, M.E. Levison, et al.
Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.
Circulation, 111 (2005), pp. e394-e434
[21.]
Modelos experimentales en patología infecciosa. Fundación Dr. Antonio Esteve,
[22.]
S. Edberg.
The measurement of antibiotics in human body fluids: techniques and signifigance.
Antibiotics in laboratory medicine,
[23.]
J. Gavalda, P.J. Cardona, B. Almirante, J.A. Capdevila, M. Laguarda, L. Pou, et al.
Treatment of experimental endocarditis due to Enterococcus faecalis using once daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.
Antimicrob Agents Chemother, 40 (1996), pp. 173-178
[24.]
J.M. Miro, C. García de la Mària, Y. Armero, E. De Lazzari, D. Soy, A. Moreno, et al.
Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
Antimcrob Agents Chemother, 51 (2007), pp. 2373-2377
[25.]
F. Marco, C. García de la Mària, Y. Armero, E. Amat, D. Soy, A. Moreno, et al.
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
Antimicrob Agents Chemother, 52 (2008), pp. 2538-2543
[26.]
J. Martinez-Lacasa, C. Cabellos, A. Martos, A. Fernández, F. Tubau, P.F. Viladrich, et al.
Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis.
J Antimicrob Chemother, 49 (2002), pp. 507-513
[27.]
M.J. Rodríguez-Hernández, J. Pachón, C. Pichardo, L. Cuberos, J. Ibáñez-Martínez, A. García-Curiel, et al.
Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia.
J Antimicrob Chemother, 45 (2000), pp. 493-501
[28.]
A. Domenech, S. Ribes, C. Cabellos, M.A. Domínguez, A. Montero, J. Linares, et al.
A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections.
Microb Drug Resist, 10 (2004), pp. 346-353
[29.]
J.A. Capdevila, J. Gavaldà, J. Fortea, P. López, M.T. Martin, X. Gomis, et al.
Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibioticlock technique.
Clin Microbiol Infect, 7 (2001), pp. 206-212
[30.]
P.J. Cardona, I. Amat, S. Gordillo, V. Arcos, E. Guirado, J. Diaz, et al.
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
Vaccine, 23 (2005), pp. 1393-1398
[31.]
J. Gavaldà, M.T. Martín, P. López, X. Gomis, J.L. Ramírez, D. Rodríguez, et al.
Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.
Antimicrob Agents Chemother, 49 (2005), pp. 3028-3030
[32.]
J. Joseph, N. Saubi, E. Pezzat, J.M. Gatell.
Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
Expert Rev Vaccines, 5 (2006), pp. 827-838
[33.]
R.E. Gagnon, A.J. Macnab, F.A. Gagnon.
A quantitative ranking of Canada's research output of original human studies for the decade 1989 to 1998.
Can Med Ass J, 162 (2000), pp. 37-40
[34.]
L. Heffer, C. Tempfer, C. Kainz.
Geography of biomedical publications in the European Union, 1990-98.
[35.]
J.M. Ramos-Rincón, M.M. Masía, F. Gutiérrez.
Producción científica en España en enfermedades infecciosas (1991-2001): posición en el contexto de la Unión Europea.
Enferm Infecc Microbiol Clin, 22 (2004), pp. 22-28
[36.]
Institute for Scientific Information Web of Knowledge. Disponible en: www.isinet.com
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos